SANTIAGO (Reuters) – Sinovac’s COVID-19 vaccine was 58.5% effective in preventing symptomatic infection among millions of Chileans who received it between February and July, the Chilean health authorities said in a report published on Tuesday.
Coronavac was 86% effective in preventing hospitalisation, 89.7% effective in preventing admission to intensive care units and 86% effective in preventing deaths within the population, health official Rafael Araos said in a press conference.
In April, the same study found that Sinovac was 67% effective in preventing symptompatic illness.
(Reporting by Aislinn Laing; Editing by Chris Reese)
